Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €19.49 EUR
Change Today +0.70 / 3.73%
Volume 156.2K
NANO On Other Exchanges
EN Paris
As of 11:38 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

nanobiotix (NANO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/22/14 - €25.00
52 Week Low
04/22/14 - €13.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANOBIOTIX (NANO)

Related News

No related news articles were found.

nanobiotix (NANO) Related Businessweek News

No Related Businessweek News Found

nanobiotix (NANO) Details

Nanobiotix S.A., a clinical-stage nanomedicine company, engages in the development of tools for the treatment of cancer. Its product pipeline includes NanoXray products comprising NBTXR3 nanoparticles that are designed for direct injection into the tumor; NBTX-IV nanoparticles designed for intravenous injection to reach the tumor and the surrounding tissue; and NBTX-TOPO nanoparticles, a gel applied during surgery after removal of the tumor in various types of breast cancer, brain tumors, and retroperitoneal soft tissue sarcomas. The company also develops nanoMag magnetic particles for treatment and diagnostic of cancer; and nanoPDT laser activated nanoparticles for the treatment of cancer. It has a licensing contract with PharmaEngine, Inc. for the development of NBTXR3; and business and development collaboration with Malaysian Biotech Corp. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Founded in 2003

nanobiotix (NANO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nanobiotix (NANO) Key Developments

Nanobiotix SA Reports Audited Consolidated Earnings Results for the Fiscal Year Ended December 31, 2014

Nanobiotix SA reported audited consolidated earnings results for the fiscal year ended December 31, 2014. Total revenue was €2,770,795 against €1,595,466 a year ago. Core operating loss was €9,619,777 against €8,179,418 a year ago. Net loss was €9,556,525 against €8,144,920 a year ago. Revenue increased mainly as a result of a milestone payment received from PharmaEngine to develop the Soft Tissue Sarcoma indication in theAsia-Pacific region. Core pre-tax loss was €9,477,255 against €8,144,920 a year ago. Sales were €967,500 against €184,938 a year ago.

Nanobiotix Announces New Manufacturing Unit

NANOBIOTIX announced it has appointed CordenPharma as its manufacturing partner. The opening of a new manufacturing line and the scaling up of production is an important step in NBTXR3™s route to commercialization. The new manufacturing line, located in France, will increase the amount of NBTXR3 product available. With an anticipated award of a CE mark in 2016, the company is preparing to scale-up production further to meet the needs of future commercialization. Furthermore, Nanobiotix is anticipating future demand from clinical trials in the coming years in Europe and in the United States.

Nanobiotix SA Reports Revenue Results for the Fourth Quarter and Year Ended December 31, 2014

Nanobiotix SA reported revenue results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of EUR 832,337 compared to EUR 46,631 in the last quarter. For the year, the company reported revenue of EUR 972,908 compared to EUR 190,068 in the last quarter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NANO:FP €19.49 EUR +0.70

NANO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NANO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NANO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOBIOTIX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at